[
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=42f3e8d79f9e8bbb88cab1a38d65e41a6e681637ba8faa2f131bc2c0b067c684",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738687020,
      "headline": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 132567499,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=42f3e8d79f9e8bbb88cab1a38d65e41a6e681637ba8faa2f131bc2c0b067c684"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release",
    "summary": "Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=e1b79362b9f3fe3b8702c0fca20a6f7cacec33bfd9aae5fa912b09fb802deced",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738681239,
      "headline": "Gilead Sciences (GILD) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release",
      "id": 132631701,
      "image": "https://media.zenfs.com/en/zacks.com/7853de8d69faeccb7d1ad6ebba40b8a2",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=e1b79362b9f3fe3b8702c0fca20a6f7cacec33bfd9aae5fa912b09fb802deced"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?",
    "summary": "Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in earnings.  The biotech just won regulatory approval for Journavx (formerly known as suzetrigine) for the treatment of acute pain -- the sort of pain you may have after an accident or surgery.  Today, with this new Vertex option available, is this biotech player a no-brainer buy?",
    "url": "https://finnhub.io/api/news?id=fc5fb277d30a75837730e24a369dd8cd57b9f233abc7f6558b3072217d445b6f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738671000,
      "headline": "Vertex Pharma Just Scored a Major FDA Approval. Is the Stock a No-Brainer Buy Now?",
      "id": 132631702,
      "image": "https://g.foolcdn.com/editorial/images/806256/gettyimages-1253877215.jpg",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex Pharmaceuticals (NASDAQ: VRTX) has long been known as the company to turn to for life-saving cystic fibrosis (CF) drugs, and this platform has helped it generate billions of dollars in earnings.  The biotech just won regulatory approval for Journavx (formerly known as suzetrigine) for the treatment of acute pain -- the sort of pain you may have after an accident or surgery.  Today, with this new Vertex option available, is this biotech player a no-brainer buy?",
      "url": "https://finnhub.io/api/news?id=fc5fb277d30a75837730e24a369dd8cd57b9f233abc7f6558b3072217d445b6f"
    }
  },
  {
    "ts": null,
    "headline": "US Stocks Estimated To Be Trading Below Intrinsic Value In February 2025",
    "summary": "As of February 2025, U.S. stock markets have been experiencing heightened volatility due to recent tariff announcements and ongoing concerns about trade policies, which have impacted major indices like the S&P 500 and Nasdaq Composite. Amidst this uncertainty, investors are increasingly focused on identifying stocks that may be trading below their intrinsic value, offering potential opportunities for those seeking to navigate the current market landscape effectively.",
    "url": "https://finnhub.io/api/news?id=af77b97e88911ce9c94dac0176bed0fe2b4e343da064cf7d9f407ba9d4a8696b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1738663340,
      "headline": "US Stocks Estimated To Be Trading Below Intrinsic Value In February 2025",
      "id": 132631703,
      "image": "https://media.zenfs.com/en/simply_wall_st__316/ee047812921f935c11e8b8a18a28c857",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "As of February 2025, U.S. stock markets have been experiencing heightened volatility due to recent tariff announcements and ongoing concerns about trade policies, which have impacted major indices like the S&P 500 and Nasdaq Composite. Amidst this uncertainty, investors are increasingly focused on identifying stocks that may be trading below their intrinsic value, offering potential opportunities for those seeking to navigate the current market landscape effectively.",
      "url": "https://finnhub.io/api/news?id=af77b97e88911ce9c94dac0176bed0fe2b4e343da064cf7d9f407ba9d4a8696b"
    }
  }
]